ESC 365 - Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial

ESC Professional Premium Access

Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial

Session: Renal failure and cardiovascular disease 2

Topic: Renal Failure and Cardiovascular Disease

Speaker: Doctor A. Pettersson Meyer (DK)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Anna Sina Pettersson Meyer

(Denmark)

0 follower

5 more presentations in this session

Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

Speaker: Doctor K. Mahaffey (Stanford, US)

CAD in kidney transplant recipients: a real-world assessment pre-ISCHEMIA-CKD

Speaker: Doctor B. Rocha (Lisbon, PT)

Epigenetic regulation of miR-181c-5p in a cardiorenal mouse model with co-occurring thrombotic microangiopathy

Speaker: Ms J. Boen (Antwerp, BE)

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

Speaker: Doctor A. Singh (Boston, US)

The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients

Speaker: Associate Professor W. Wongcharoen (Chiang Mai, TH)

Access the full session

Renal failure and cardiovascular disease 2

Speakers: Doctor A. Pettersson Meyer, Doctor K. Mahaffey, Doctor B. Rocha, Ms J. Boen, Doctor A. Singh...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources